On May 22, 2023, the U.S. Food and Drug Administration approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis. Avapritinib had previously been approved for advanced systemic mastocytosis in
On May 22, 2023, the U.S. Food and Drug Administration approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis. Avapritinib had previously been approved for advanced systemic mastocytosis in
More